A BILL to amend and reenact § 38.2-4319 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 38.2-3418.23, relating to health insurance; coverage for speech therapy as a treatment for stuttering.
HB64 would require certain Virginia health insurers, health service plans, and health maintenance organizations to cover both habilitative and rehabilitative speech therapy when used to treat stuttering. The bill defines those terms and specifies that coverage must apply whether the stuttering is developmental or otherwise classified, so long as the plan already covers habilitative or rehabilitative services. It also directs that the required coverage cannot be capped by annual benefit limits or visit limits, cannot be restricted based on the underlying cause of the stuttering, and cannot be subjected to prior authorization or other utilization management requirements, including a medical-necessity determination.
The bill excludes short-term travel, accident-only, limited or specified disease policies, Medicare-related policies, and certain short-term nonrenewable policies. It also includes a federal cost-defrayal safeguard: if the mandate would require the Commonwealth to pay for the coverage under federal law, the mandate would not take effect until that requirement no longer applies. The bill would apply to policies, contracts, and health care plans delivered, issued for delivery, or renewed in Virginia on and after January 1, 2027.
HB64 would amend Virginia insurance law by adding a new mandated-benefit section, § 38.2-3418.23, and by updating § 38.2-4319 to incorporate that new provision into the statutory framework governing health maintenance organizations. In practical terms, it would expand coverage obligations for individual and group accident and sickness insurers, subscription contracts, and HMOs that already cover habilitative or rehabilitative services, while limiting the ability of carriers to impose visit caps, annual caps, prior authorization, or medical-necessity review for stuttering-related speech therapy. The bill would affect insurers, HMOs, covered policyholders, and speech-language pathology providers, and it would take effect for new or renewed coverage beginning January 1, 2027.
The available context shows little recorded debate or voting activity, so there is no strong evidence of organized opposition or support in the transcript record. The bill’s introduction and referral suggest it was treated as a health insurance mandate proposal, but the absence of committee transcripts and votes means sentiment must be inferred from the bill’s sponsorship and subject matter. Overall, the measure appears to have been presented as a consumer- and patient-protection bill aimed at improving access to speech therapy for people who stutter.
The main points of potential contention are the insurance mandate itself and the limits on insurer utilization controls. Carriers may object to being required to cover speech therapy without annual visit limits, prior authorization, or medical-necessity review, especially because the bill applies regardless of whether stuttering is developmental. Another possible issue is the breadth of the mandate’s interaction with existing law and federal coverage rules, including the cost-defrayal provision that delays application if state payment obligations would be triggered. No specific opposing speakers or committee objections are available in the provided record.